OTC Markets EXMKT - Delayed Quote USD

0913693 B.C. Ltd. (REPCF)

Compare
0.0020
0.0000
(0.00%)
As of April 3 at 4:00:00 PM EDT. Market Open.
Loading Chart for REPCF
  • Previous Close 0.0000
  • Open 0.0428
  • Bid --
  • Ask --
  • Day's Range 0.0428 - 0.0428
  • 52 Week Range 0.0002 - 0.0428
  • Volume 550
  • Avg. Volume 516
  • Market Cap (intraday) 147,156
  • Beta (5Y Monthly) 0.93
  • PE Ratio (TTM) --
  • EPS (TTM) -0.0100
  • Earnings Date May 14, 2025 - May 19, 2025
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

0913693 B.C. Ltd., a regenerative medicine company, focuses on developing autologous cell therapies that treat functional cellular deficits. Its treatments use autologous cell therapy to treat chronic tendon injuries, androgenetic alopecia, and skin aging by restoring cellular function to rejuvenate aging or sun damaged skin, regrow hair, and repair tendons. The company's product candidates include RCH-01, a cell therapy for pattern baldness; RCS-01, a cell therapy for aging or sun damaged skin; and RCT-01, a cell therapy for tendon degeneration. It is also developing DermaPrecise, a dermal injection device. The company has a licensing and collaborative agreement with YOFOTO (China) Health Industry Co. Ltd. to develop and commercialize programs. The company was formerly known as RepliCel Life Sciences Inc. and changed its name to 0913693 B.C. Ltd. in March 2025. 0913693 B.C. Ltd. is based in Vancouver, Canada.

www.replicel.com

--

Full Time Employees

December 31

Fiscal Year Ends

Recent News: REPCF

View More

Performance Overview: REPCF

Trailing total returns as of 4/4/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

REPCF
100.00%
S&P 500 (^GSPC)
11.95%

1-Year Return

REPCF
95.33%
S&P 500 (^GSPC)
0.61%

3-Year Return

REPCF
98.48%
S&P 500 (^GSPC)
13.00%

5-Year Return

REPCF
98.89%
S&P 500 (^GSPC)
108.09%

Compare To: REPCF

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: REPCF

View More

Valuation Measures

Annual

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -27.50%

  • Return on Assets (ttm)

    -103.50%

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    353.74k

  • Net Income Avi to Common (ttm)

    -97.29k

  • Diluted EPS (ttm)

    -0.0100

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    1.81k

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -238.41k

Research Analysis: REPCF

View More

Company Insights: REPCF

Research Reports: REPCF

View More

People Also Watch